Lenvatinib intermediate, preparation thereof and preparation of lenvatinib

A technology of lenvatinib and intermediates, applied in the field of pharmaceutical chemical synthesis, to achieve the effects of cheap and easy-to-obtain reaction raw materials, avoid the use of organic solvents, and simplify the process route

Inactive Publication Date: 2018-12-14
CHENGDU DIAO PHARMA GROUP
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0022] In view of the deficiencies and defects existing in the prior art, seek a kind of process step is simple, environmental pollution is little, and cost is low, especially the key intermediate 1-(2-chloro-4-hydroxybenzene of lenvatinib that does

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lenvatinib intermediate, preparation thereof and preparation of lenvatinib
  • Lenvatinib intermediate, preparation thereof and preparation of lenvatinib
  • Lenvatinib intermediate, preparation thereof and preparation of lenvatinib

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0065] (1) Compared with the reagent phenyl chloroformate used in the preparation of the existing lenvatinib intermediate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (compound E), the present invention The reagent CDI (N,N'-carbonyldiimidazole) used is more environmentally friendly and cheap and easy to obtain. And it is also possible to directly use water as a solvent, and directly precipitate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea with a purity greater than 98.5% from the water phase after the reaction, avoiding the reaction process and after-treatment The use of a large amount of organic solvents in the treatment process is more environmentally friendly.

[0066] (2) react with compound CDI earlier by cyclopropylamine and then react with 4-amino-3-chlorophenol to obtain key intermediate E, and then react with 4-chloro-7-methoxyquinoline-6-formamide (compound F) Condensation can greatly reduce the side reactions caused by the fact that 4-amino-3-chlorophenol has ...

Embodiment 1

[0074] Example 1: Synthesis of 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (compound E)

[0075] Step 1: Synthesis of N-cyclopropyl-1H-imidazole-1-carboxamide (Compound I)

[0076]

[0077] In a 250ml round-bottomed flask, add cyclopropylamine (10g, 0.175mol) and 50ml of water as a solvent, place it in an ice bath, add CDI (51.08g, 0.315mol) in three batches, after the addition is complete, continue at 0°C After reacting for 1 h, TLC monitored that the reaction was complete, and the reaction mixture was directly carried out to the next reaction without any post-treatment.

[0078] Step 2: Synthesis of 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (compound E)

[0079]

[0080] To the untreated N-cyclopropyl-1H-imidazole-1-carboxamide (Compound I) aqueous solution obtained in Step 1, directly add raw material 4-amino-3-chlorophenol (Compound A) (17.7g, 0.123mol) , the reaction mixture was heated in an oil bath at 78°C, and after 4 hours, TLC monitored that the react...

Embodiment 2

[0081]Example 2: Synthesis of 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (compound E)

[0082] Step 1: Synthesis of N-cyclopropyl-1H-imidazole-1-carboxamide (Compound I)

[0083]

[0084] In a 250ml round-bottomed flask, add cyclopropylamine (10g, 0.175mol) and 30ml of water as a solvent, place it in an ice bath, add CDI (51.08g, 0.315mol) in three batches, after the addition is complete, continue at 25°C After reacting for 1 h, TLC monitored that the reaction was complete, and the reaction mixture was directly carried out to the next reaction without any post-treatment.

[0085] Step 2: Synthesis of 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea (compound E)

[0086]

[0087] To the untreated N-cyclopropyl-1H-imidazole-1-carboxamide (Compound I) aqueous solution obtained in Step 1, directly add raw material 4-amino-3-chlorophenol (Compound A) (17.7g, 0.123mol) , the reaction mixture was heated in an oil bath at 78°C, and after 4 hours, TLC monitored that the react...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of drug synthesis and discloses a lenvatinib key intermediate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea, preparation thereof and preparation of lenvatinib. Thelenvatinib intermediate has purity higher than 99% and is prepared by the following steps: (1) cyclopropylamine is subjected to reaction with a compound N,N'-carbonyldiimidazole in a solvent, and N-cyclopropyl-1H-imidazole-1-formamide is obtained; (2) N-cyclopropyl-1H-imidazole-1-formamide and 4-amino-3-chlorophenol are subjected to reaction, and 1-(2-chloro-hydroxyphenyl)-cyclopropylurea is obtained. The intermediate 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea and 4-chloro-7-methoxyquinoline-6-carboxamide are subjected to reaction, and a final product lenvatinib is obtained. The preparation methods are simple to operate, raw materials are cheap and easily available, few difficult-to-remove impurities are produced, water is directly used as a solvent, an organic solvent is not needed, the purity of the product can be higher than 99% with low environmental pollution and simple post-processing, and the methods are green, environmentally friendly, economic and suitable for large-scaleindustrial production.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical chemical synthesis, and in particular relates to an aqueous phase preparation method of a key intermediate of lenvatinib and its application in the synthesis of lenvatinib. Background technique [0002] Lenvatinib (lenvatinib) is an oral multi-receptor tyrosine kinase inhibitor developed by Japan's Eisai Company, which has a novel binding mode and targets vascular endothelial growth factor receptor (VEGFR) 1-3 , fibroblast growth factor receptor (FGFR) 1-3, platelet-derived growth factor receptor (PDGFR) of the stem cell growth factor receptor beta type. On February 13, 2015, the FDA approved its listing for the treatment of locally recurrent or metastatic, aggressive, radioactive iodine-refractory differentiated thyroid cancer; on May 13, 2016, the FDA approved the combination of lenvatinib and everolimus For the treatment of advanced metastatic renal cell carcinoma. In addition, Eisai i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D215/48C07C275/34C07C273/18
CPCC07C273/1836C07D215/48C07C2601/02C07C275/34
Inventor 何鹏王学超邓塔何倩
Owner CHENGDU DIAO PHARMA GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap